Clinical Scorecard: Analyzing Prognostic and Immune Characteristics of Kidney Renal Clear Cell Carcinoma through Mitochondria-Associated Membranes and Identifying DNM1L as a Potential Target for Therapy Using Machine Learning Techniques

At a Glance

Key Highlights

• KIRC accounts for over 70% of renal cell carcinoma cases.
• Approximately 20%-30% of patients present with distant metastases at diagnosis.
• MAMs are implicated in cancer cell metabolism and therapeutic resistance.
• Machine learning models were developed to predict prognosis based on MAMs-related gene expression.
• DNM1L identified as a potential therapeutic target in KIRC.

Guideline-Based Recommendations

Diagnosis

• Utilize RNA sequencing data for accurate diagnosis and characterization of KIRC.

Management

• Consider immunotherapy and targeted therapies as part of the treatment regimen for metastatic KIRC.

Monitoring & Follow-up

• Implement prognostic scoring models based on MAMs-related gene expression to monitor disease progression.

Risks

• Patients with localized RCC have a 30% risk of recurrence and progression to metastatic disease.

Patient & Prescribing Data

537 KIRC patients analyzed from TCGA and additional datasets.

Machine learning models can enhance the prediction of patient outcomes and guide therapeutic decisions.

Clinical Best Practices

• Incorporate machine learning algorithms to refine prognostic models for KIRC.
• Regularly assess the expression of MAMs-related genes to inform treatment strategies.
• Utilize comprehensive datasets for external validation of prognostic models.

References

• The Cancer Genome Atlas (TCGA)
• ArrayExpress database
• GEO repository
• The Cancer Immunome Atlas (TCIA)